FDA approves wider range of treatments for cancer drug

A drug previously approved to treat different skin cancers recently got a Food and Drug Administration greenlight to treat a few more.

Dr. Davor Vugrin, a hematologist and oncologist in Lubbock, said Keytruda already proved to be effective against several skin cancers. The FDA’s approval now includes treatment for types of colorectal cancer, gastrointestinal cancer, breast cancer, prostate cancer, bladder cancer, thyroid cancer and more.


The FDA granted an accelerated approval of Keytruda in May to treat tumors that originate from specific genetic biomarkers.


A press release from the FDA says about 39.6 percent of the 149 patients who participated in clinical trials for Keytruda showed a complete or partial tumor shrinkage. The response lasted for six months or more for about 78 percent of those patients, according to the press release.


“It’s quite an exciting drug,” Vugrin said.


Cancer treatment drugs have traditionally been approved by the FDA based on their location on the body, Vugrin said. This is the first time a drug has received FDA approval based on a genetic feature.


Dr. Patrick Reynolds, professor and director of the cancer center for the Texas Tech’s Health Sciences Center, said the accelerated approval means responses in the clinical trials were favorable.


It’s not unusual for drugs to be placed in the accelerated approval track, he said. Keytruda is unique.


It works by targeting the root of a genetic-based cancer and blocks T cells in the body from allowing it to replicate, he said.


T cells are an essential part of the immune system, Reynolds said.


“T cells are the immune cells in our body that recognize cells that are not supposed to be there,” he said. “If you transplant tissue from somebody else in you, that’s what’s going to reject it.”


When a mutation slips into a DNA strand, it often leads to cancer, he said.


“When we get mutations, you don’t usually get Wolverine or X-Men,” Reynolds said. “You get cancer.”


That’s why T cells are important in controlling cancers, he said.


Vugrin said Keytruda targets the T cells and makes them aware of the cancer and blocks them from aiding in the production of more cancer cells.


“The basic mechanism of how it works is by sort of helping the immune system to fight the cancer cell,” Vugrin said.


Keytruda has been effective in treating skin cancers like melanoma, he said. It’s also been approved to treat lung cancers and colorectal cancers.

Related Stories

Remembering Dr. Tom McGovern

TTUHSC Celebration of Life Service was held March 25th in remembrance of Tom McGovern, Ed.D.

TTUHSC Ranks Fourth Nationally Among Graduate Institutions as a Military Friendly® School

TTUHSC has been named as a Military Friendly® School for 2022-2023. Among graduate schools, TTUHSC ranked fourth in the nation, achieving Gold award status.

TTUHSC Jerry H. Hodge School of Pharmacy Students Celebrate Residency Assignments on Match Day

On March 16, fourth-year TTUHSC Jerry H. Hodge School of Pharmacy students interested in completing a residency after they graduate in May, learned where they would spend the next stage of their training during the Pharmacy Residency Match Day.

Recent Stories


Startups Begin Here! Four Startups Awarded $50,000 from TTUHSC President

The Innovation Hub at Research Park today (September 26, 2022) announced the winners of its annual Presidents' Innovative Startup Awards. The award recognizes startups that have a high potential for growth and an economic impact in West Texas.


Fifth Graders Become Doctors for a Day

Fifth graders from Bean Elementary School became doctors for a day. The Texas Tech University Health Sciences Center (TTUHSC) Student National Medical Association (SNMA) hosted the Doctors for a Day Minicamp on Sept. 23.


New Study Explains Mechanisms of Salt Transport and Could Help Treat Cystic Fibrosis

Pablo Artigas, Ph.D., from TTHSC's School of Medicine’s Department of Cell Physiology and Molecular Biophysics, published a study with his team of collaborators in Nature Communications.